Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.

Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea. Dig Dis Sci (2017) 0.75

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14

Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35

Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2011) 12.09

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88

Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56

Crohn's disease. Lancet (2012) 4.42

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut (2013) 3.49

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology (2015) 2.82

Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis (2008) 2.70

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol (2014) 2.39

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut (2013) 1.87

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol (2012) 1.66

Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res (2016) 1.47

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut (2014) 1.40

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol (2010) 1.35

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology (2014) 1.35

Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol (2013) 1.26

Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol (2014) 1.22

Long-term prognosis of crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis (2014) 1.21

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol (2011) 0.94

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol (2013) 0.94

Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep (2014) 0.90

Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2013) 0.88

A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays. Inflamm Bowel Dis (2016) 0.87

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther (2015) 0.85

Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis (2011) 0.85

Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis (2014) 0.85

Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am (2014) 0.83

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology (2003) 0.82

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther (2016) 0.81

Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time? Gastroenterology (2015) 0.79

Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn's Disease: A Hospital-Based Cohort Study. Dig Dis Sci (2016) 0.77